A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Percentage of Participants With HCV RNA < 1000 International Units Per Milliliter (IU/mL)

Analysis of participants with HCV RNA levels below 1000 IU/mL at Week 2.

Time frame: Week 2

Percentage of Participants With HCV RNA Below the Lower Limit of Quantitation (LLOQ; <25 IU/mL) at Week 4

Analysis of percentage of participants with hepatitis C virus ribonucleic acid less than the lower limit of quantitation (\< 25 IU/mL).

Time frame: Week 4

Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment

Sustained virologic response 12 (SVR12) is defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (LLOQ; \< 25 IU/mL) 12 weeks after the last dose of study drug.

Time frame: Post-treatment Day 1 to Post-treatment Week 12

Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment

Sustained virologic response 24 (SVR24) is defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (LLOQ; \< 25 IU/mL) 24 weeks after the last dose of study drug.

Time frame: Post-treatment Day 1 to Post-treatment Week 24

Time to Failure to Suppress or Rebound During Treatment

Time to failure to achieve a 2 log10 IU/mL HCV RNA decrease at Week 1, failure to achieve HCV RNA \< Lower Limit of Detection (LLOD) at Week 6, or a confirmed increase of at least 0.5 log10 IU/mL above nadir (local minimum value) or confirmed HCV RNA \> lower limit of quantitation (LLOQ) for participants who previously achieved HCV RNA \< LLOQ.

Time frame: Day 1 through Week 12

Time to Virologic Relapse Post-treatment

Time to the first of 2 consecutive measurements of confirmed HCV RNA ≥ lower limit of quantitation (LLOQ) at any point in the post-treatment period among participants with HCV RNA \< LLOQ at the end of treatment.

Time frame: Post-treatment Day 1 to post-treatment week 48

Resistance-Associated Variants and Phenotypic Resistance

Baseline samples were analyzed for resistance-associated amino acid variants using population sequencing. Phenotypic resistance to ABT-450 or ABT-333 at baseline was assessed by calculating the fold difference in the half maximal effective concentration (EC50) compared with the EC50 for the appropriate reference replicon (1a-H77 or 1b-Con1). Participants not achieving SVR12 were analyzed for resistance-associated variants at the time of failure using population sequencing and were compared with the baseline and appropriate reference sequences to assess amino acid changes. Phenotypic resistance to ABT-450 or ABT-333 at the time of failure was assessed by calculating the fold difference in the EC50 compared with the EC50 for the corresponding baseline sample. The number of participants with variants at resistance-associated amino acid positions and phenotypic resistance at baseline and at the time of failure are presented.

Time frame: Day 1 to post-treatment week 48

Pharmacokinetics (C Trough) of ABT 450 in HCV Infected Participants

Trough concentration (C trough) is the concentration 24 hours after once daily (QD) dose and 12 hours after twice daily (BID) dose.

Time frame: Day 1 to Week 12

Pharmacokinetics (C Trough) of ABT-333 in HCV Infected Participants

Trough concentration (C trough) is the concentration 24 hours after once daily (QD) dose and 12 hours after twice daily (BID) dose.

Time frame: Day 1 to Week 12

Pharmacokinetics (C Trough) of Ritonavir in HCV Infected Participants

Trough concentration (C trough) is the concentration 24 hours after once daily (QD) dose and 12 hours after twice daily (BID) dose.

Time frame: Day 1 to Week 12

Pharmacokinetics (C Trough) of Ribavirin in HCV Infected Participants

Trough concentration (C trough) is the concentration 24 hours after once daily (QD) dose and 12 hours after twice daily (BID) dose.

Time frame: Day 1 to Week 12